Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former's pipeline amid significant vaccine policy changes in the US. The transaction, for a price of $15.50 per share in cash, is expected to close in the first quarter of 2026. Through the deal, Sanofi will acquire Dynavax's hepatitis B vaccine HEPLISAV-B. The product won approval in the US and Europe in 2017 and 2021, respectively. Sanofi does not currently have a hepatitis B vacc ...

What AI bubble? New research from Bank of America has thrown cold water on the growing narrative, and instead focuses on the upside the firm sees in chipmakers.The firm recently laid out its forecast for the coming year in a note to clients, predicting that the AI market will experience some volatility but ultimately finish the year strong as data center buildouts continue and companies double down on manufacturing and equipment spending. The analysts view the AI market as being roughly halfway through a ...

We’re closing in on the end of 2025 at record-shattering levels for the S&P 500, and it’s not a time for complacency. In my view, now is a time for active portfolio management, and investors have to take tremendous care to ensure that ourWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He has been a regular cont ...

Key Takeaways Ocugen's phase III liMeliGhT study of OCU400 in RP nears enrollment, with top-line data expected in Q4 2026.OCGN's OCU410ST for Stargardt disease is in phase II/III, with interim data expected in mid-2026.Ocugen expects phase II data for OCU410 in GA in Q1 2026, with phase III slated for mid-2026.Ocugen (OCGN) is making rapid progress in its gene therapy programs for retinal diseases, which have differentiated mechanisms of action. With all three key pipeline programs moving on schedule, Ocuge ...

nCino (NCNO) closed the last trading session at $26.29, gaining 6.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.73 indicates a 32.1% upside potential.The mean estimate comprises 15 short-term price targets with a standard deviation of $4.08. While the lowest estimate of $27.00 indicates a 2.7% increase from the current price level, the most optimistic analyst expects the s ...

BREAKING: Stocks Open Lower In Quiet Trade Today's Spotlight Leaderboard New Year's Sale Get a head start on your 2026 investing resolutions with 1 month of Leaderboard for only $29. Get Market Insights on IBD Live Join IBD Live to watch and discuss the market action in real time with a team of top market analysts. Is the Santa Claus Rally Real? Something big may be coming to town—check out IBD's guide to the Santa Claus Rally. (© Chris Gash) Next Data Center Roadblock For Google, Microsoft, Oracle, Meta Is ...

Key Takeaways MindMed is enrolling two phase III GAD studies with top-line data due in 2026. MNMD's phase III Emerge study in MDD enrolled faster, with top-line data now expected in mid-2026.MindMed shares rose 101.2% in six months. A $258.9M financing strengthens its balance sheet.Mind Medicine (MindMed) (MNMD) is developing its lead pipeline candidate MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate, for the treatment of generalized anxiety disorde ...

Key Points Mid-cap stocks boast a better long-term track record of performance than large caps. This hasn’t been the case of late mostly because of a once-in-a-generation tech revolution. Picking individual mid-cap tickers can be a lot of work, and so an ETF can be more sensible. 10 stocks we like better than Vanguard Index Funds - Vanguard Mid-Cap ETF › Anyone who has been in the stock market for long enough has likely heard the merits of index fund investing. They're simple to own and often pr ...

Shares of Greenwich LifeSciences Inc. (GLSI) have been on a tear over the past ten days as the clinical-stage biotech pushes ahead with its financing strategy and prepares to implement risk-reducing modifications to the phase III trial of its investigational breast cancer immunotherapy, GLSI-100, upon the regulatory go-ahead.GLSI-100 is a combination of GP2 peptide vaccine and GM-CSF, an immune system booster, which is designed to help the body recognize and fight cancer cells that express the HER2/neu pro ...

交易结构与监管审视 - 英伟达与Grok达成的是一份非排他性许可协议，但支付了巨额资金，交易结构设计引发关注 [2] - 前反垄断官员指出，若交易结构旨在规避《哈特-斯科特-罗迪诺法案》规定的强制申报义务，其本身可能构成非法的“规避手段” [4] - 监管机构需确保此类通过非排他性许可、反向人才收购等方式进行的交易不会成为规避审查的标准做法 [5] 交易实质与竞争影响 - 尽管形式上是许可协议，但英伟达获得了Grok的关键技术和几乎所有重要员工，支付高昂代价，其性质类似收购 [7][8] - Grok在推理领域具备竞争优势，其LPU技术能以更快、更便宜、能耗更低的方式处理某些工作负载，与英伟达形成竞争 [11][12] - 交易引发的关键竞争拷问是：英伟达是否通过获取直接竞争对手的技术和员工，削弱了一个本可能成长并夺走其更多业务的潜在威胁 [13] 监管应对与行业观察 - 此次交易已引起反垄断界的注意，监管机构应将其作为收购案进行调查，评估其竞争后果 [6][8] - 在科技市场，竞争威胁未必来自全栈竞争对手，像Grok这样在特定环节（如推理）具有优势的公司也可能构成威胁 [10][11] - 监管机构需要仔细审视交易是否具有竞争性影响，即使目标公司并非全栈竞争者 [9]